13hpode

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Lebrikizumab, an IgG4 humanized monoclonal antibody, specifically targets and inhibits interleukin-13 (IL-13), thus impacting its function. This compound is utilized in asthma research [1].

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).

Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequence T cells. Rolinsatamab can be used to prevent and treat immune diseases.

Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding to IL-13Rα1 subunit. Abrezekimab can be used to study biological disorders associated with asthma and lung disease.

Anrukinzumab (IMA-638), a humanized anti-IL-13 monoclonal antibody, effectively reduces lung inflammation in cynomolgus monkeys and shows potential in the studies of ulcerative colitis (UC) and asthma [1] [2] [3].

Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.

Dectrekumab (QAX576) is a humanized monoclonal antibody targeting IL-13 that reduces the number of eosinophils in the epithelium of patients with eosinophilic esophagitis (EoE), ameliorates transcriptional dysregulation associated with esophageal disease, and is indicated for use in the study of immune system disorders.

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin (Ig) antibody specifically designed to target interleukins 4 and 13 (IL-4 and IL-13) [1].

Rademikibart (CBP-201) is a human monoclonal antibody selective for IL-4Rα, exhibiting strong affinity with a KD of 20.7 pM for human IL-4Rα epitopes, without cross-reactivity to IL-4Rα from other species. It effectively inhibits IL-4 and IL-13-induced STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMCs, showing promise for investigating moderate-to-severe Th2 inflammatory diseases [1].

Lunsekimig (SAR443765) is an IL-13 TSLP bis-antibody that links a nano-antibody targeting IL-13 and a variable region of the heavy chain (VHH) targeting TSLP for use in asthma research.

CNTO 607 (Anti-IL-13 Antibody) is a humanized antibody targeting IL-13, used in inflammation research.

Riltovetbart is a monoclonal antibody against IL-13, the isotype control is IgG2 κ, and its origin is canine.